SRPT vs WES · rev $1.13B vs P/E 12, rev $3.84B
Sarepta Therapeutics Inc (SRPT) versus Western Midstream Partners LP (WES) — a side-by-side from cached financials, not a winner call.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Western Midstream Partners LP (WES) is a oil & gas midstream company listed on US.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
Latest reported WES revenue for 2025-12-31 was $3.84B. Net income was $1.18B. Revenue was up 6.6% from 2024-12-31 to 2025-12-31. WES currently screens at market cap $14.85B and trailing P/E 11.7.
SRPT currently screens at market cap $2.34B. WES currently screens at market cap $14.85B and trailing P/E 11.7.
Not investment advice. Open the SRPT and WES stock pages for the full models.
Not investment advice.